It is a common resistance mechanism to EGFR tyrosine kinase inhibitor (TKI) therapy in NSCLC with or without EGFR mutations, resulting in activation of downstream pathways, and is associated with a poor prognosis. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.